{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:47:06Z","timestamp":1792900026815,"version":"4.5.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immune checkpoint inhibitors are a class of drugs used in cancer treatment that promote the immune system\u2019s response by blocking the inhibitor signals from tumour cells, such as programmed cell death protein 1\/programmed death ligand 1 and cytotoxic T-lymphocyte associated protein 4. Despite their clinical benefit, these monoclonal antibodies unspecifically activate the immune system and can lead to the development of \u2018immune-related adverse events\u2019. Cutaneous toxicities are the most frequent immune-related adverse events, reported in approximately 30\u201350% of patients treated with immunotherapy; the most common dermatological toxicities are represented by rash, vitiligo, pruritus and lichenoid reactions. Usually, these reactions are mild and it is not necessary to suspend immunotherapy. Potentially life-threatening skin toxicities, such as immunobullous eruption, are rare and may appear in approximately 1% of patients. In this report we describe a case of bullous pemphigoid, the most frequent bullous disease, that developed after treatment with pembrolizumab for a metastatic melanoma. The diagnosis, first suspected by the referring clinic, was confirmed by performing serology and biopsy with direct immunofluorescence. The patient was first treated with high doses of systemic corticosteroids, without suspending the immunotherapy treatment. Subsequently, due to the continuous relapses, we decided to suspend pembrolizumab and systemic corticosteroid and to begin off-label treatment with dupilumab. The following case gives cause for reflection about the management of a drug-induced disease in an immunocompromised patient, while exploring the therapeutic options.<\/jats:p>","DOI":"10.1093\/skinhd\/vzae023","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T20:19:26Z","timestamp":1735849166000},"page":"70-74","source":"Crossref","is-referenced-by-count":7,"title":["A case of pembrolizumab-induced bullous pemphigoid treated with dupilumab"],"prefix":"10.1093","volume":"5","author":[{"given":"Agnese","family":"Rossi","sequence":"first","affiliation":[{"name":"Dermatology Department, Polytechnic University of Marche , Ancona, Marche ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Brancorsini","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Polytechnic University of Marche , Ancona ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Gioacchini","sequence":"additional","affiliation":[{"name":"Dermatology Department, Polytechnic University of Marche , Ancona, Marche ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Campanati","sequence":"additional","affiliation":[{"name":"Dermatology Department, Polytechnic University of Marche , Ancona, Marche ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"2025031806245170300_vzae023-B1","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.3390\/cancers14215451","article-title":"A retrospective, single-institution experience of bullous pemphigoid as an adverse effect of immune checkpoint inhibitors","volume":"14","author":"Shalata","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025031806245170300_vzae023-B2","doi-asserted-by":"crossref","first-page":"1095694","DOI":"10.3389\/fonc.2023.1095694","article-title":"Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"2025031806245170300_vzae023-B3","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/ijd.13984","article-title":"A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors","volume":"57","author":"Lopez","year":"2018","journal-title":"Int J Dermatol"},{"key":"2025031806245170300_vzae023-B4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J Cutan Pathol"},{"key":"2025031806245170300_vzae023-B5","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"2025031806245170300_vzae023-B6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/ced.13042","article-title":"Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression","volume":"42","author":"Rofe","year":"2017","journal-title":"Clin Exp Dermatol"},{"key":"2025031806245170300_vzae023-B7","doi-asserted-by":"crossref","first-page":"928621","DOI":"10.3389\/fimmu.2022.928621","article-title":"Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review","volume":"13","author":"Cao","year":"2022","journal-title":"Front Immunol"},{"key":"2025031806245170300_vzae023-B8","doi-asserted-by":"crossref","first-page":"1196946","DOI":"10.3389\/fmed.2023.1196946","article-title":"Targeting type 2 inflammation in bullous pemphigoid: current and emerging therapeutic approaches","volume":"10","author":"Toh","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2025031806245170300_vzae023-B9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40257-023-00832-1","article-title":"Advancements in bullous pemphigoid treatment: a comprehensive pipeline update","volume":"25","author":"Karakioulaki","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"2025031806245170300_vzae023-B10","doi-asserted-by":"crossref","first-page":"1194088","DOI":"10.3389\/fimmu.2023.1194088","article-title":"Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types","volume":"14","author":"Yan","year":"2023","journal-title":"Front Immunol"},{"key":"2025031806245170300_vzae023-B11","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.3390\/jcm11123367","article-title":"Use of dupilumab in bullous pemphigoid: where are we now?","volume":"11","author":"Russo","year":"2022","journal-title":"J Clin Med"},{"issue":"Pt A","key":"2025031806245170300_vzae023-B12","doi-asserted-by":"crossref","first-page":"111157","DOI":"10.1016\/j.intimp.2023.111157","article-title":"Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: a prospective cohort study","volume":"125","author":"Huang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"2025031806245170300_vzae023-B13","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/bjd\/ljad149","article-title":"Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment","volume":"189","author":"Shipman","year":"2023","journal-title":"Br J Dermatol"},{"key":"2025031806245170300_vzae023-B14","doi-asserted-by":"crossref","first-page":"1157250","DOI":"10.3389\/fimmu.2023.1157250","article-title":"Biological treatment for bullous pemphigoid","volume":"14","author":"Oren-Shabtai","year":"2023","journal-title":"Front Immunol"},{"key":"2025031806245170300_vzae023-B15","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/5\/1\/70\/61900129\/vzae023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/5\/1\/70\/61900129\/vzae023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T06:25:07Z","timestamp":1742279107000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/5\/1\/70\/8015693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3,18]]}},"URL":"https:\/\/doi.org\/10.1093\/skinhd\/vzae023","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2025,2]]}}}